Care profits hit SAR 247.5M in 9M 2025; Q3 at SAR 82.2M

02/11/2025 Argaam Exclusive

View other reports

National Medical Care Co. (Care) reported net profits of SAR 247.5 million for the first nine months of 2025, compared to SAR 211 million in the same period of 2024.

Financials (M)

Item	9m 2024	9m 2025	Change‬
Revenues	921.15	1,195.61	29.8 %
Gross Income	329.86	441.93	34.0 %
Operating Income	208.33	272.58	30.8 %
Net Income	210.97	247.51	17.3 %
Average Shares	44.85	44.85	-
Earnings Per Share before unusual items (Riyals)	4.06	5.52	36.0 %
EPS (Riyal)	4.70	5.52	17.3 %

The company said the profit increase was mainly driven by higher revenue, which reached SAR 1.2 billion, supported by a 41% year-on-year (YoY) rise in the number of patients to 710,810.

It attributed the growth to higher referrals from key clients, improved performance across affiliated hospitals, and the consolidation of newly acquired branches.

Care said cost optimization also supported gross profit, operating profit, and EBITDA.

However, the net profit margin declined due to a one-off Zakat provision settlement of about SAR 29 million booked in the comparative period last year, in addition to higher Zakat expenses and financing costs in the first nine months of 2025.

Current Quarter Comparison (M)

Compared With The

Item	Q3 2024	Q3 2025	Change‬
Revenues	325.77	412.41	26.6 %
Gross Income	111.51	151.47	35.8 %
Operating Income	70.87	90.40	27.6 %
Net Income	60.19	82.20	36.6 %
Average Shares	44.85	44.85	-
Earnings Per Share before unusual items (Riyal)	1.34	1.83	36.6 %
EPS (Riyal)	1.34	1.83	36.6 %

Item	Q2 2025	Q3 2025	Change‬
Revenues	397.87	412.41	3.7 %
Gross Income	147.48	151.47	2.7 %
Operating Income	84.98	90.40	6.4 %
Net Income	79.94	82.20	2.8 %
Average Shares	44.85	44.85	-
Earnings Per Share before unusual items (Riyal)	1.78	1.83	2.8 %
EPS (Riyal)	1.78	1.83	2.8 %

Care’s Q3 2025 net profit rose 36.6% to SAR 82.2 million, compared with SAR 60.19 million a year earlier. Sequentially, net profit increased 2.8% from SAR 79.94 million in Q2 2025.

Shareholders’ equity, no minority interest, reached SAR 1.78 billion by Sept. 30, 2025, compared to SAR 1.54 billion in a year earlier period.

Attached Documents

View More Financial Results

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2016	253.94	15.7 %	67.29	24.3 %	35.04	20.3 %
Q2 2016	259.77	14.0 %	84.30	29.8 %	61.24	58.0 %
Q3 2016	197.01	(6.5 %)	50.54	(0.5 %)	27.99	3.2 %
Q4 2016	189.94	(13.9 %)	4.86	(90.3 %)	(44.59)	(232.3 %)
2016	900.65	2.5 %	206.99	(6.0 %)	94.75	(26.4 %)
Q1 2017	202.44	(20.3 %)	41.19	(38.8 %)	14.04	(59.9 %)
Q2 2017	216.54	(16.6 %)	50.25	(40.4 %)	20.01	(67.3 %)
Q3 2017	208.34	5.8 %	46.97	(7.1 %)	26.33	(5.9 %)
Q4 2017	227.76	19.9 %	57.00	1072.0 %	29.59	166.4 %
2017	855.08	(5.1 %)	195.40	(5.6 %)	89.97	(5.1 %)
Q1 2018	206.67	2.1 %	51.73	25.6 %	28.41	102.4 %
Q2 2018	199.05	(8.1 %)	49.59	(1.3 %)	23.40	17.0 %
Q3 2018	176.40	(15.3 %)	33.17	(29.4 %)	13.16	(50.0 %)
Q4 2018	181.69	(20.2 %)	32.02	(43.8 %)	14.93	(49.6 %)
2018	763.80	(10.7 %)	166.51	(14.8 %)	79.90	(11.2 %)
Q1 2019	179.43	(13.2 %)	48.01	(7.2 %)	30.31	6.7 %
Q2 2019	169.94	(14.6 %)	38.26	(22.8 %)	15.56	(33.5 %)
Q3 2019	173.51	(1.6 %)	40.11	20.9 %	19.63	49.2 %
Q4 2019	185.52	2.1 %	39.27	22.6 %	22.88	53.3 %
2019	708.39	(7.3 %)	165.66	(0.5 %)	88.37	10.6 %
Q1 2020	195.02	8.7 %	52.22	8.8 %	36.28	19.7 %
Q2 2020	186.04	9.5 %	58.87	53.9 %	29.77	91.4 %
Q3 2020	213.31	22.9 %	51.06	27.3 %	22.70	15.6 %
Q4 2020	214.60	15.7 %	61.73	57.2 %	25.36	10.9 %
2020	808.95	14.2 %	223.88	35.1 %	114.11	29.1 %
Q1 2021	214.19	9.8 %	63.64	21.9 %	42.18	16.3 %
Q2 2021	202.49	8.8 %	57.77	(1.9 %)	37.59	26.3 %
Q3 2021	213.11	(0.1 %)	63.08	23.5 %	39.80	75.3 %
Q4 2021	215.59	0.5 %	61.98	0.4 %	36.65	44.5 %
2021	845.38	4.5 %	246.47	10.1 %	156.22	36.9 %
Q1 2022	211.48	(1.3 %)	61.44	(3.5 %)	35.17	(16.6 %)
Q2 2022	216.49	6.9 %	66.80	15.6 %	45.95	22.2 %
Q3 2022	238.28	11.8 %	82.71	31.1 %	49.06	23.3 %
Q4 2022	251.69	16.7 %	78.74	27.0 %	58.74	60.3 %
2022	917.94	8.6 %	289.68	17.5 %	188.92	20.9 %
Q1 2023	261.40	23.6 %	89.88	46.3 %	58.48	66.3 %
Q2 2023	245.19	13.3 %	81.34	21.8 %	54.10	17.7 %
Q3 2023	275.36	15.6 %	91.78	11.0 %	73.90	50.6 %
Q4 2023	299.84	19.1 %	106.64	35.4 %	56.21	(4.3 %)
2023	1,081.78	17.8 %	369.63	27.6 %	242.70	28.5 %
Q1 2024	298.56	14.2 %	110.20	22.6 %	71.05	21.5 %
Q2 2024	296.82	21.1 %	108.16	33.0 %	63.18	16.8 %
Q3 2024	325.77	18.3 %	111.51	21.5 %	70.87	(4.1 %)
Q4 2024	372.54	24.2 %	124.23	16.5 %	44.44	(20.9 %)
2024	1,293.69	19.6 %	454.08	22.8 %	248.22	2.3 %
Q1 2025	385.32	29.1 %	142.98	29.7 %	96.55	35.9 %
Q2 2025	397.87	34.0 %	147.48	36.4 %	84.98	34.5 %
Q3 2025	412.41	26.6 %	151.47	35.8 %	90.40	27.6 %

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2015	878.67	19.7 %	220.20	24.2 %	128.69	38.9 %
2016	900.65	2.5 %	206.99	(6.0 %)	94.75	(26.4 %)
2017	855.08	(5.1 %)	195.40	(5.6 %)	89.97	(5.1 %)
2018	763.80	(10.7 %)	166.51	(14.8 %)	79.90	(11.2 %)
2019	708.39	(7.3 %)	165.66	(0.5 %)	88.37	10.6 %
2020	808.95	14.2 %	223.88	35.1 %	114.11	29.1 %
2021	845.38	4.5 %	246.47	10.1 %	156.22	36.9 %
2022	917.94	8.6 %	289.68	17.5 %	188.92	20.9 %
2023	1,081.78	17.8 %	369.63	27.6 %	242.70	28.5 %
2024	1,293.69	19.6 %	454.08	22.8 %	248.22	2.3 %

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS(Riyal)
Q1 2016	33.12	19.5 %	0.74	-	33.12	0.74
Q2 2016	59.29	40.2 %	1.32	-	59.29	1.32
Q3 2016	27.55	8.2 %	0.61	-	27.55	0.61
Q4 2016	(69.69)	(297.8 %)	(1.55)	(33.75)	(35.95)	(0.80)
2016	50.27	(61.5 %)	1.12	(33.75)	84.02	1.87
Q1 2017	15.54	(53.1 %)	0.35	-	15.54	0.35
Q2 2017	19.50	(67.1 %)	0.43	-	19.50	0.43
Q3 2017	27.00	(2.0 %)	0.60	-	27.00	0.60
Q4 2017	23.26	133.4 %	0.52	(1.24)	24.50	0.55
2017	85.30	69.7 %	1.90	(1.24)	86.54	1.93
Q1 2018	25.60	64.8 %	0.57	-	25.60	0.57
Q2 2018	20.26	3.9 %	0.45	-	20.26	0.45
Q3 2018	11.44	(57.6 %)	0.26	-	11.44	0.26
Q4 2018	4.87	(79.1 %)	0.11	-	4.87	0.11
2018	62.18	(27.1 %)	1.39	-	62.18	1.39
Q1 2019	29.99	17.1 %	0.67	-	29.99	0.67
Q2 2019	13.81	(31.8 %)	0.31	-	13.81	0.31
Q3 2019	16.64	45.4 %	0.37	-	16.64	0.37
Q4 2019	19.64	303.2 %	0.44	-	19.64	0.44
2019	80.09	28.8 %	1.79	-	80.09	1.79
Q1 2020	33.17	10.6 %	0.74	-	33.17	0.74
Q2 2020	25.78	86.6 %	0.57	-	25.78	0.57
Q3 2020	16.32	(1.9 %)	0.36	-	16.32	0.36
Q4 2020	22.00	12.0 %	0.49	-	22.00	0.49
2020	97.27	21.4 %	2.17	-	97.27	2.17
Q1 2021	35.73	7.7 %	0.80	-	35.73	0.80
Q2 2021	30.74	19.2 %	0.69	-	30.74	0.69
Q3 2021	33.17	103.2 %	0.74	-	33.17	0.74
Q4 2021	36.71	66.9 %	0.82	-	36.71	0.82
2021	136.36	40.2 %	3.04	-	136.36	3.04
Q1 2022	30.00	(16.0 %)	0.67	-	30.00	0.67
Q2 2022	42.01	36.7 %	0.94	-	42.01	0.94
Q3 2022	42.62	28.5 %	0.95	-	42.62	0.95
Q4 2022	55.45	51.0 %	1.24	-	55.45	1.24
2022	170.07	24.7 %	3.79	-	170.07	3.79
Q1 2023	56.27	87.6 %	1.25	-	56.27	1.25
Q2 2023	47.80	13.8 %	1.07	-	47.80	1.07
Q3 2023	73.38	72.2 %	1.64	-	73.38	1.64
Q4 2023	63.48	14.5 %	1.42	-	63.48	1.42
2023	240.93	41.7 %	5.37	-	240.93	5.37
Q1 2024	81.29	44.5 %	1.81	15.84	65.45	1.46
Q2 2024	69.50	45.4 %	1.55	13.17	56.32	1.26
Q3 2024	60.19	(18.0 %)	1.34	-	60.19	1.34
Q4 2024	87.19	37.3 %	1.94	42.34	44.86	1.00
2024	298.16	23.8 %	6.65	71.35	226.82	5.06
Q1 2025	85.37	5.0 %	1.90	-	85.37	1.90
Q2 2025	79.94	15.0 %	1.78	-	79.94	1.78
Q3 2025	82.20	36.6 %	1.83	-	82.20	1.83

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS(Riyal)
2015	130.72	36.9 %	2.91	-	130.72	2.91
2016	50.27	(61.5 %)	1.12	(33.75)	84.02	1.87
2017	85.30	69.7 %	1.90	(1.24)	86.54	1.93
2018	62.18	(27.1 %)	1.39	-	62.18	1.39
2019	80.09	28.8 %	1.79	-	80.09	1.79
2020	97.27	21.4 %	2.17	-	97.27	2.17
2021	136.36	40.2 %	3.04	-	136.36	3.04
2022	170.07	24.7 %	3.79	-	170.07	3.79
2023	240.93	41.7 %	5.37	-	240.93	5.37
2024	298.16	23.8 %	6.65	71.35	226.82	5.06

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2016	25.56 %	21.44 %	14.91 %
Q2 2016	26.74 %	23.27 %	16.20 %
Q3 2016	27.11 %	23.91 %	16.67 %
Q4 2016	22.98 %	16.07 %	9.33 %
2016	22.98 %	17.75 %	9.33 %
Q1 2017	21.30 %	14.58 %	7.82 %
Q2 2017	18.22 %	10.27 %	3.31 %
Q3 2017	17.53 %	9.96 %	3.19 %
Q4 2017	22.85 %	18.52 %	10.12 %
2017	22.85 %	18.52 %	10.12 %
Q1 2018	23.97 %	20.17 %	11.24 %
Q2 2018	24.39 %	20.91 %	11.57 %
Q3 2018	23.64 %	20.41 %	10.10 %
Q4 2018	21.80 %	20.00 %	8.14 %
2018	21.80 %	20.00 %	8.14 %
Q1 2019	22.10 %	21.08 %	9.04 %
Q2 2019	21.41 %	21.09 %	8.50 %
Q3 2019	22.48 %	21.77 %	9.27 %
Q4 2019	23.38 %	22.17 %	11.31 %
2019	23.38 %	22.17 %	11.31 %
Q1 2020	23.46 %	22.32 %	11.50 %
Q2 2020	25.74 %	23.29 %	12.87 %
Q3 2020	25.83 %	22.00 %	12.17 %
Q4 2020	27.68 %	21.05 %	12.02 %
2020	27.68 %	21.05 %	12.02 %
Q1 2021	28.41 %	20.86 %	12.06 %
Q2 2021	27.73 %	21.19 %	12.41 %
Q3 2021	29.16 %	23.15 %	14.41 %
Q4 2021	29.15 %	24.41 %	16.13 %
2021	29.15 %	24.41 %	16.13 %
Q1 2022	28.99 %	23.58 %	15.50 %
Q2 2022	29.57 %	24.02 %	16.56 %
Q3 2022	30.95 %	24.24 %	17.16 %
Q4 2022	31.56 %	25.56 %	18.53 %
2022	31.56 %	25.56 %	18.53 %
Q1 2023	32.87 %	26.57 %	20.29 %
Q2 2023	33.38 %	26.76 %	20.28 %
Q3 2023	33.06 %	28.54 %	22.53 %
Q4 2023	34.17 %	27.51 %	22.27 %
2023	34.17 %	27.51 %	22.27 %
Q1 2024	34.85 %	28.22 %	22.35 %
Q2 2024	35.60 %	28.19 %	22.09 %
Q3 2024	35.75 %	27.00 %	20.10 %
Q4 2024	35.10 %	25.51 %	17.53 %
2024	35.10 %	25.41 %	17.53 %
Q1 2025	35.27 %	26.39 %	17.87 %
Q2 2025	35.52 %	26.59 %	18.25 %
Q3 2025	36.10 %	-	18.64 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2015	25.06 %	21.32 %	14.88 %
2016	22.98 %	17.75 %	9.33 %
2017	22.85 %	18.52 %	10.12 %
2018	21.80 %	20.00 %	8.14 %
2019	23.38 %	22.17 %	11.31 %
2020	27.68 %	21.05 %	12.02 %
2021	29.15 %	24.41 %	16.13 %
2022	31.56 %	25.56 %	18.53 %
2023	34.17 %	27.51 %	22.27 %
2024	35.10 %	25.41 %	17.53 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2016	26.50 %	20.19 %	13.04 %
Q2 2016	32.45 %	29.83 %	22.83 %
Q3 2016	25.65 %	22.64 %	13.99 %
Q4 2016	2.56 %	(15.05 %)	(18.93 %)
Q1 2017	20.35 %	15.00 %	7.68 %
Q2 2017	23.20 %	16.81 %	9.01 %
Q3 2017	22.54 %	20.74 %	12.96 %
Q4 2017	25.02 %	21.25 %	10.76 %
Q1 2018	25.03 %	21.90 %	12.39 %
Q2 2018	24.91 %	19.67 %	10.18 %
Q3 2018	18.81 %	18.43 %	6.49 %
Q4 2018	17.62 %	19.73 %	2.68 %
Q1 2019	26.76 %	26.61 %	16.71 %
Q2 2019	22.51 %	19.46 %	8.13 %
Q3 2019	23.12 %	21.16 %	9.59 %
Q4 2019	21.17 %	21.29 %	10.59 %
Q1 2020	26.78 %	26.82 %	17.01 %
Q2 2020	31.64 %	23.57 %	13.86 %
Q3 2020	23.94 %	16.85 %	7.65 %
Q4 2020	28.77 %	17.82 %	10.25 %
Q1 2021	29.71 %	25.54 %	16.68 %
Q2 2021	28.53 %	24.72 %	15.18 %
Q3 2021	29.60 %	24.62 %	15.57 %
Q4 2021	28.75 %	22.79 %	17.03 %
Q1 2022	29.05 %	22.23 %	14.19 %
Q2 2022	30.86 %	26.41 %	19.40 %
Q3 2022	34.71 %	25.37 %	17.89 %
Q4 2022	31.28 %	27.80 %	22.03 %
Q1 2023	34.38 %	26.61 %	21.53 %
Q2 2023	33.17 %	27.22 %	19.49 %
Q3 2023	33.33 %	32.22 %	26.65 %
Q4 2023	35.57 %	24.22 %	21.17 %
Q1 2024	36.91 %	29.36 %	21.92 %
Q2 2024	36.44 %	27.28 %	18.98 %
Q3 2024	34.23 %	27.15 %	18.48 %
Q4 2024	33.35 %	19.58 %	12.04 %
Q1 2025	37.11 %	31.65 %	22.15 %
Q2 2025	37.07 %	27.81 %	20.09 %
Q3 2025	36.73 %	-	19.93 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
Q1 2016	44.85	3.03	3.03	20.60
Q2 2016	44.85	3.41	3.41	21.16
Q3 2016	44.85	3.46	3.46	21.75
Q4 2016	44.85	1.12	1.87	20.18
Q1 2017	44.85	0.73	1.48	20.51
Q2 2017	44.85	(0.16)	0.59	20.93
Q3 2017	44.85	(0.17)	0.58	21.52
Q4 2017	44.85	1.90	1.93	21.98
Q1 2018	44.85	2.13	2.15	22.38
Q2 2018	44.85	2.14	2.17	21.83
Q3 2018	44.85	1.80	1.82	22.09
Q4 2018	44.85	1.39	1.39	22.23
Q1 2019	44.85	1.48	1.48	22.90
Q2 2019	44.85	1.34	1.34	22.20
Q3 2019	44.85	1.46	1.46	22.57
Q4 2019	44.85	1.79	1.79	23.03
Q1 2020	44.85	1.86	1.86	23.77
Q2 2020	44.85	2.12	2.12	22.34
Q3 2020	44.85	2.12	2.12	22.71
Q4 2020	44.85	2.17	2.17	23.12
Q1 2021	44.85	2.23	2.23	23.92
Q2 2021	44.85	2.34	2.34	23.60
Q3 2021	44.85	2.71	2.71	24.34
Q4 2021	44.85	3.04	3.04	25.07
Q1 2022	44.85	2.91	2.91	25.74
Q2 2022	44.85	3.16	3.16	25.67
Q3 2022	44.85	3.37	3.37	26.62
Q4 2022	44.85	3.79	3.79	28.17
Q1 2023	44.85	4.38	4.38	29.43
Q2 2023	44.85	4.51	4.51	29.49
Q3 2023	44.85	5.19	5.19	31.13
Q4 2023	44.85	5.37	5.37	32.41
Q1 2024	44.85	5.93	5.58	34.22
Q2 2024	44.85	6.41	5.77	33.61
Q3 2024	44.85	6.12	5.47	34.35
Q4 2024	44.85	6.65	5.06	36.33
Q1 2025	44.85	6.74	5.50	38.24
Q2 2025	44.85	6.97	6.03	38.03
Q3 2025	44.85	7.46	6.52	39.86

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
2015	44.85	2.91	2.91	20.01
2016	44.85	1.12	1.87	20.18
2017	44.85	1.90	1.93	21.98
2018	44.85	1.39	1.39	22.23
2019	44.85	1.79	1.79	23.03
2020	44.85	2.17	2.17	23.12
2021	44.85	3.04	3.04	25.07
2022	44.85	3.79	3.79	28.17
2023	44.85	5.37	5.37	32.41
2024	44.85	6.65	5.06	36.33

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Recurring P/E	Price/book
Q1 2016	16.69	16.69	2.46
Q2 2016	18.71	18.71	3.02
Q3 2016	15.98	15.98	2.54
Q4 2016	58.81	35.19	3.27
Q1 2017	73.26	36.05	2.60
Q2 2017	NEG	79.11	2.25
Q3 2017	NEG	69.35	1.87
Q4 2017	22.90	22.57	1.98
Q1 2018	26.45	26.11	2.51
Q2 2018	27.67	27.32	2.72
Q3 2018	25.44	25.05	2.07
Q4 2018	36.28	36.28	2.26
Q1 2019	31.56	31.56	2.05
Q2 2019	43.34	43.34	2.62
Q3 2019	37.22	37.22	2.40
Q4 2019	27.22	27.22	2.11
Q1 2020	19.53	19.53	1.53
Q2 2020	19.83	19.83	1.88
Q3 2020	26.08	26.08	2.43
Q4 2020	24.62	24.62	2.31
Q1 2021	24.08	24.08	2.24
Q2 2021	29.10	29.10	2.88
Q3 2021	23.12	23.12	2.58
Q4 2021	20.59	20.59	2.50
Q1 2022	28.53	28.53	3.23
Q2 2022	17.07	17.07	2.10
Q3 2022	21.46	21.46	2.72
Q4 2022	19.49	19.49	2.62
Q1 2023	20.60	20.60	3.07
Q2 2023	28.53	28.53	4.36
Q3 2023	23.69	23.69	3.95
Q4 2023	32.47	32.47	5.38
Q1 2024	31.33	33.32	5.43
Q2 2024	33.21	36.94	6.34
Q3 2024	33.76	37.75	6.01
Q4 2024	25.03	32.90	4.60
Q1 2025	23.80	29.16	4.20
Q2 2025	23.45	27.12	4.30
Q3 2025	23.62	27.05	4.42

Period	P/E	Recurring P/E	Price/book
2015	19.04	19.04	2.77
2016	58.81	35.19	3.27
2017	22.90	22.57	1.98
2018	36.28	36.28	2.26
2019	27.22	27.22	2.11
2020	24.62	24.62	2.31
2021	20.59	20.59	2.50
2022	19.49	19.49	2.62
2023	32.47	32.47	5.38
2024	25.03	32.90	4.60

Business Segments (Million)

Compared With The

Period	Medical Services	Pharmacies
Q1 2016	220.78	33.16
Q2 2016	230.14	29.62
Q3 2016	173.08	23.93
Q4 2016	162.66	27.28
Q1 2017	176.04	26.40
Q2 2017	190.13	26.41
Q3 2017	185.07	23.27
Q4 2017	202.08	25.76
Q1 2018	183.47	23.20
Q2 2018	175.85	23.20
Q3 2018	155.67	20.74
Q4 2018	154.94	26.74
Q1 2019	157.71	21.72
Q2 2019	149.87	20.07
Q3 2019	153.76	19.76
Q4 2019	162.79	22.72
Q1 2020	170.81	24.20
Q2 2020	164.47	21.52
Q3 2020	187.44	25.56
Q4 2020	192.76	22.19
Q1 2021	188.50	25.70
Q2 2021	178.18	24.30
Q3 2021	187.54	25.57
Q4 2021	188.78	26.82
Q1 2022	169.18	42.30
Q2 2022	207.43	9.06
Q3 2022	209.69	28.59
Q4 2022	221.11	30.57
Q1 2023	230.03	31.37
Q2 2023	215.77	29.42
Q3 2023	241.54	33.83
Q4 2023	264.88	34.95
Q1 2024	262.73	35.83
Q2 2024	261.20	35.62
Q3 2024	287.60	38.17
Q4 2024	330.64	41.90
Q1 2025	342.16	43.16
Q2 2025	352.53	45.35

Period	Medical Services	Pharmacies
2015	753.38	125.28
2016	786.66	113.99
2017	753.32	101.85
2018	669.93	93.87
2019	624.13	84.27
2020	715.48	93.47
2021	742.99	102.39
2022	807.41	110.52
2023	952.21	129.57
2024	1,142.17	151.52

Analysts Estimates (Million)

Item	Profit (Expected)	Profit (Actual)	Change
Average	81.03	82.20

Estimates vs Actual (Million)

Item	Profit (Expected)	Profit (Actual)
Sico	83.20	82.20
YAQEEN	81.00	82.20
AlJazira Capital	89.90	82.20
United Securities Company	70.00	82.20

Financial Ratios

	Current
Market Cap (M Riyal)	7,220.86
Enterprise Value (EV) (M Riyal)	7,021.91
Shares Outstanding ((M))	44.85
EPS ( Riyal) (TTM)	7.46
Book Value (BV) ( Riyal)	39.86
Par Value ( Riyal)	10.00
Recurring P/E	24.70
P/E (TTM)	21.57
Price/book	4.04
Return on Average Assets (%) (TTM)	13.9
Return on Average Equity (%) (TTM)	20.1
EV/adj EBITDA	-
EV/Revenues	4.48

National Medical Care Co. (CARE)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Care profits hit SAR 247.5M in 9M 2025; Q3 at SAR 82.2M

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2025 Q3

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

National Medical Care Co. (CARE)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

×

Care profits hit SAR 247.5M in 9M 2025; Q3 at SAR 82.2M

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q2 2025

Revenue by Business Segment (Latest) 2025 Q3

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

National Medical Care Co. (CARE)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Business Segments (Million)